Using Molecular Symmetry to Form New Drugs: Hydroxymethyl-Substituted 3,9-Diazatetraasteranes as the First Class of Symmetric MDR Modulators
More is not always better: Until now it was considered that modulators of P‐glycoprotein‐associated multidrug resistance in cancer treatment showed greater inhibitory activity with an increasing number of moieties that could participate in hydrogen bonds. This theory has been questioned for the firs...
Gespeichert in:
| Veröffentlicht in: | Angewandte Chemie International Edition 2002-10, Vol.41 (19), p.3623-3625 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3625 |
|---|---|
| container_issue | 19 |
| container_start_page | 3623 |
| container_title | Angewandte Chemie International Edition |
| container_volume | 41 |
| creator | Hilgeroth, Andreas Molnár, Jósef De Clercq, Eric |
| description | More is not always better: Until now it was considered that modulators of P‐glycoprotein‐associated multidrug resistance in cancer treatment showed greater inhibitory activity with an increasing number of moieties that could participate in hydrogen bonds. This theory has been questioned for the first time with a new class of symmetrical inhibitors 1 based on hydroxymethyl‐3,9‐diazatetraasteranes. |
| doi_str_mv | 10.1002/1521-3773(20021004)41:19<3623::AID-ANIE3623>3.0.CO;2-V |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72156384</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72156384</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4083-d4f478f79c9aec2bddd254ba82dd10f93156c58a323be33c32e3baa165629f8a3</originalsourceid><addsrcrecordid>eNqVkdtu1DAQhiMEogd4BeQrBFK92J4ct6jSKtttF7W7gtLtBRcjJ3HaQNIU21EbnoGHxtEeuOKCK9vjf75_NL_nnXA24oyJDzwQnEIUwTvhnq7kv_f5mCcfIRQwHk_mUzpZzE-H1wmM2ChdHgu6eubt7xqfu7sPQKM44HvegTHfHSiOWfjS2-MCIpZwtu_9vjbV_S25bGuVd7XU5KpvGmV1T2xLZq1uyEI9kqnubs2YnPeFbp9693_X1_Sqy4ytbGdVQeAoodNK_pLW9UpprNLyXhkiDbF3iswqbSxJa2kMacutR5WTy-kX5104Z9tq88p7UcraqNeb89C7np1-Tc_pxfJsnk4uaO6zGGjhl34Ul1GSJ1LlIiuKQgR-JmNRFJyVCfAgzINYgoBMAeQgFGRS8jAIRVK6-qH3ds190O3PThmLTWVyVddu5rYzGAlHgNh3wtVamOvWGK1KfNBVI3WPnOGQEw7rxmHduM0JfY48wSEZRJcTbnNCQIbpEgWuHPjNZoIua1TxF7sJxgm-rQWPVa36_7T9h-uu5uh0Ta9cUk87utQ_MIwgCvBmcYZJID7fBJ84MvgDqha-Lw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72156384</pqid></control><display><type>article</type><title>Using Molecular Symmetry to Form New Drugs: Hydroxymethyl-Substituted 3,9-Diazatetraasteranes as the First Class of Symmetric MDR Modulators</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Hilgeroth, Andreas ; Molnár, Jósef ; De Clercq, Eric</creator><creatorcontrib>Hilgeroth, Andreas ; Molnár, Jósef ; De Clercq, Eric</creatorcontrib><description>More is not always better: Until now it was considered that modulators of P‐glycoprotein‐associated multidrug resistance in cancer treatment showed greater inhibitory activity with an increasing number of moieties that could participate in hydrogen bonds. This theory has been questioned for the first time with a new class of symmetrical inhibitors 1 based on hydroxymethyl‐3,9‐diazatetraasteranes.</description><identifier>ISSN: 1433-7851</identifier><identifier>EISSN: 1521-3773</identifier><identifier>DOI: 10.1002/1521-3773(20021004)41:19<3623::AID-ANIE3623>3.0.CO;2-V</identifier><identifier>PMID: 12370910</identifier><language>eng</language><publisher>Weinheim: WILEY-VCH Verlag</publisher><subject>Animals ; Antineoplastic Agents - chemical synthesis ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; ATP Binding Cassette Transporter, Sub-Family B - antagonists & inhibitors ; ATP Binding Cassette Transporter, Sub-Family B - metabolism ; cage compounds ; Drug Design ; Drug Resistance, Multiple ; Drug Resistance, Neoplasm ; Heterocyclic Compounds - chemical synthesis ; Heterocyclic Compounds - chemistry ; Heterocyclic Compounds - pharmacology ; MDR modulators ; medicinal chemistry ; Mice ; Molecular Structure ; photochemistry ; structure-activity relationships ; Tumor Cells, Cultured</subject><ispartof>Angewandte Chemie International Edition, 2002-10, Vol.41 (19), p.3623-3625</ispartof><rights>2002 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F1521-3773%2820021004%2941%3A19%3C3623%3A%3AAID-ANIE3623%3E3.0.CO%3B2-V$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F1521-3773%2820021004%2941%3A19%3C3623%3A%3AAID-ANIE3623%3E3.0.CO%3B2-V$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12370910$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hilgeroth, Andreas</creatorcontrib><creatorcontrib>Molnár, Jósef</creatorcontrib><creatorcontrib>De Clercq, Eric</creatorcontrib><title>Using Molecular Symmetry to Form New Drugs: Hydroxymethyl-Substituted 3,9-Diazatetraasteranes as the First Class of Symmetric MDR Modulators</title><title>Angewandte Chemie International Edition</title><addtitle>Angewandte Chemie International Edition</addtitle><description>More is not always better: Until now it was considered that modulators of P‐glycoprotein‐associated multidrug resistance in cancer treatment showed greater inhibitory activity with an increasing number of moieties that could participate in hydrogen bonds. This theory has been questioned for the first time with a new class of symmetrical inhibitors 1 based on hydroxymethyl‐3,9‐diazatetraasteranes.</description><subject>Animals</subject><subject>Antineoplastic Agents - chemical synthesis</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>ATP Binding Cassette Transporter, Sub-Family B - antagonists & inhibitors</subject><subject>ATP Binding Cassette Transporter, Sub-Family B - metabolism</subject><subject>cage compounds</subject><subject>Drug Design</subject><subject>Drug Resistance, Multiple</subject><subject>Drug Resistance, Neoplasm</subject><subject>Heterocyclic Compounds - chemical synthesis</subject><subject>Heterocyclic Compounds - chemistry</subject><subject>Heterocyclic Compounds - pharmacology</subject><subject>MDR modulators</subject><subject>medicinal chemistry</subject><subject>Mice</subject><subject>Molecular Structure</subject><subject>photochemistry</subject><subject>structure-activity relationships</subject><subject>Tumor Cells, Cultured</subject><issn>1433-7851</issn><issn>1521-3773</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkdtu1DAQhiMEogd4BeQrBFK92J4ct6jSKtttF7W7gtLtBRcjJ3HaQNIU21EbnoGHxtEeuOKCK9vjf75_NL_nnXA24oyJDzwQnEIUwTvhnq7kv_f5mCcfIRQwHk_mUzpZzE-H1wmM2ChdHgu6eubt7xqfu7sPQKM44HvegTHfHSiOWfjS2-MCIpZwtu_9vjbV_S25bGuVd7XU5KpvGmV1T2xLZq1uyEI9kqnubs2YnPeFbp9693_X1_Sqy4ytbGdVQeAoodNK_pLW9UpprNLyXhkiDbF3iswqbSxJa2kMacutR5WTy-kX5104Z9tq88p7UcraqNeb89C7np1-Tc_pxfJsnk4uaO6zGGjhl34Ul1GSJ1LlIiuKQgR-JmNRFJyVCfAgzINYgoBMAeQgFGRS8jAIRVK6-qH3ds190O3PThmLTWVyVddu5rYzGAlHgNh3wtVamOvWGK1KfNBVI3WPnOGQEw7rxmHduM0JfY48wSEZRJcTbnNCQIbpEgWuHPjNZoIua1TxF7sJxgm-rQWPVa36_7T9h-uu5uh0Ta9cUk87utQ_MIwgCvBmcYZJID7fBJ84MvgDqha-Lw</recordid><startdate>20021004</startdate><enddate>20021004</enddate><creator>Hilgeroth, Andreas</creator><creator>Molnár, Jósef</creator><creator>De Clercq, Eric</creator><general>WILEY-VCH Verlag</general><general>WILEY‐VCH Verlag</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20021004</creationdate><title>Using Molecular Symmetry to Form New Drugs: Hydroxymethyl-Substituted 3,9-Diazatetraasteranes as the First Class of Symmetric MDR Modulators</title><author>Hilgeroth, Andreas ; Molnár, Jósef ; De Clercq, Eric</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4083-d4f478f79c9aec2bddd254ba82dd10f93156c58a323be33c32e3baa165629f8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - chemical synthesis</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>ATP Binding Cassette Transporter, Sub-Family B - antagonists & inhibitors</topic><topic>ATP Binding Cassette Transporter, Sub-Family B - metabolism</topic><topic>cage compounds</topic><topic>Drug Design</topic><topic>Drug Resistance, Multiple</topic><topic>Drug Resistance, Neoplasm</topic><topic>Heterocyclic Compounds - chemical synthesis</topic><topic>Heterocyclic Compounds - chemistry</topic><topic>Heterocyclic Compounds - pharmacology</topic><topic>MDR modulators</topic><topic>medicinal chemistry</topic><topic>Mice</topic><topic>Molecular Structure</topic><topic>photochemistry</topic><topic>structure-activity relationships</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hilgeroth, Andreas</creatorcontrib><creatorcontrib>Molnár, Jósef</creatorcontrib><creatorcontrib>De Clercq, Eric</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Angewandte Chemie International Edition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hilgeroth, Andreas</au><au>Molnár, Jósef</au><au>De Clercq, Eric</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Using Molecular Symmetry to Form New Drugs: Hydroxymethyl-Substituted 3,9-Diazatetraasteranes as the First Class of Symmetric MDR Modulators</atitle><jtitle>Angewandte Chemie International Edition</jtitle><addtitle>Angewandte Chemie International Edition</addtitle><date>2002-10-04</date><risdate>2002</risdate><volume>41</volume><issue>19</issue><spage>3623</spage><epage>3625</epage><pages>3623-3625</pages><issn>1433-7851</issn><eissn>1521-3773</eissn><abstract>More is not always better: Until now it was considered that modulators of P‐glycoprotein‐associated multidrug resistance in cancer treatment showed greater inhibitory activity with an increasing number of moieties that could participate in hydrogen bonds. This theory has been questioned for the first time with a new class of symmetrical inhibitors 1 based on hydroxymethyl‐3,9‐diazatetraasteranes.</abstract><cop>Weinheim</cop><pub>WILEY-VCH Verlag</pub><pmid>12370910</pmid><doi>10.1002/1521-3773(20021004)41:19<3623::AID-ANIE3623>3.0.CO;2-V</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1433-7851 |
| ispartof | Angewandte Chemie International Edition, 2002-10, Vol.41 (19), p.3623-3625 |
| issn | 1433-7851 1521-3773 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72156384 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Animals Antineoplastic Agents - chemical synthesis Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology ATP Binding Cassette Transporter, Sub-Family B - antagonists & inhibitors ATP Binding Cassette Transporter, Sub-Family B - metabolism cage compounds Drug Design Drug Resistance, Multiple Drug Resistance, Neoplasm Heterocyclic Compounds - chemical synthesis Heterocyclic Compounds - chemistry Heterocyclic Compounds - pharmacology MDR modulators medicinal chemistry Mice Molecular Structure photochemistry structure-activity relationships Tumor Cells, Cultured |
| title | Using Molecular Symmetry to Form New Drugs: Hydroxymethyl-Substituted 3,9-Diazatetraasteranes as the First Class of Symmetric MDR Modulators |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T09%3A34%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Using%20Molecular%20Symmetry%20to%20Form%20New%20Drugs:%20Hydroxymethyl-Substituted%203,9-Diazatetraasteranes%20as%20the%20First%20Class%20of%20Symmetric%20MDR%20Modulators&rft.jtitle=Angewandte%20Chemie%20International%20Edition&rft.au=Hilgeroth,%20Andreas&rft.date=2002-10-04&rft.volume=41&rft.issue=19&rft.spage=3623&rft.epage=3625&rft.pages=3623-3625&rft.issn=1433-7851&rft.eissn=1521-3773&rft_id=info:doi/10.1002/1521-3773(20021004)41:19%3C3623::AID-ANIE3623%3E3.0.CO;2-V&rft_dat=%3Cproquest_cross%3E72156384%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72156384&rft_id=info:pmid/12370910&rfr_iscdi=true |